Form 4: Xenon Pharmaceuticals CFO Buys Shares
Insider Transaction (Form 4)
Thomas Patrick Kelly, Chief Financial Officer of Xenon Pharmaceuticals Inc., purchased 15,000 shares of common stock on September 30, 2026 for $37.32 per share.
Summary
- Open-market purchase: acquired 15,000 Common Shares at $37.32 ($559,740) on September 30, 2026; holds 15,000 after (Direct).
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $559,740, committing personal capital to the stock.
Insider Transactions
Thomas Patrick Kelly — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Open-market purchase | Common Shares | 15,000 | $37 | $559.7K | 15,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Open-market purchase (15,000 shares) |
Keywords
insider transaction, Form 4, XENE, Xenon Pharmaceuticals Inc., bullish, Thomas Patrick Kelly
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.